RxDoctor Payments Data
★ My doctorsLook up a doctor →

Naomi Seleh

Los Angeles, CANPI 1154011252

Payments from drug & device makers

$3,461in general payments, 2019–2025

Across 127 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$586
  • AstraZeneca$480
  • AbbVie$406
  • GSK$331
  • Boehringer Ingelheim$190
  • Novo Nordisk$163
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen17$586
AstraZeneca15$480
AbbVie17$406
GSK15$331
Boehringer Ingelheim7$190
Novo Nordisk7$163
Bayer5$152
Novartis6$150
Ardelyx, Inc.5$147
Radius Health, Inc.5$138
Otsuka America Pharmaceutical, Inc.5$135
Lilly USA, LLC4$101
Sumitomo Pharma America, Inc.4$88
Aimmune Therapeutics, Inc.3$78
Phathom Pharmaceuticals, Inc.2$65
Azurity Pharmaceuticals, Inc.2$50
Viatris Specialty LLC2$45
Pfizer1$37
IBSA Pharma Inc.2$36
Vertex1$32
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$26
Xeris Pharmaceuticals, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →